Vollmer TL - Search Results

1

Autoimmune encephalitis: A more treatable tragedy if diagnosed early.

Vollmer TL, McCarthy M. Vollmer TL, et al. Neurology. 2016 May 3;86(18):1655-6. doi: 10.1212/WNL.0000000000002641. Epub 2016 Apr 1. Neurology. 2016. PMID: 27037233 No abstract available.

2

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group. Vollmer TL, et al. J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. Epub 2014 Feb 18. J Neurol. 2014. PMID: 24535134 Clinical Trial.

3

To PLEX or not to PLEX in natalizumab-associated PML.

Tyler KL, Vollmer TL. Tyler KL, et al. Among authors: vollmer tl. Neurology. 2017 Mar 21;88(12):1108-1109. doi: 10.1212/WNL.0000000000003747. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228561 No abstract available.

4

Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders.

Kammeyer R, Mizenko C, Sillau S, Richie A, Owens G, Nair KV, Alvarez E, Vollmer TL, Bennett JL, Piquet AL. Kammeyer R, et al. Among authors: vollmer tl. Front Neurol. 2022 Mar 2;13:689975. doi: 10.3389/fneur.2022.689975. eCollection 2022. Front Neurol. 2022. PMID: 35309573 Free PMC article.

5

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.

Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. Sheremata WA, et al. Among authors: vollmer tl. Neurology. 1999 Mar 23;52(5):1072-4. doi: 10.1212/wnl.52.5.1072. Neurology. 1999. PMID: 10102433 Clinical Trial.

6

Mitoxantrone and cytotoxic drugs' mechanisms of action.

Vollmer T, Stewart T, Baxter N. Vollmer T, et al. Neurology. 2010 Jan 5;74 Suppl 1:S41-6. doi: 10.1212/WNL.0b013e3181c97f5a. Neurology. 2010. PMID: 20038762

7

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Kleinschmidt-DeMasters BK, et al. J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. J Neuropathol Exp Neurol. 2012. PMID: 22710964 Review.

8

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Calabresi PA, et al. Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Lancet Neurol. 2014. PMID: 24685276 Clinical Trial.

9

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Ziemssen T, et al. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705122 Free PMC article. Review.

10

Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).

Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Hebert JR, et al. Neurology. 2018 Feb 27;90(9):e797-e807. doi: 10.1212/WNL.0000000000005013. Epub 2018 Jan 31. Neurology. 2018. PMID: 29386274 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters